Brief: Applied Molecular Reports Results from Trial of AMT-101 in Patients with Chronic Pouchitis
25/04/2022 13:05
April 25 (Reuters) - Applied Molecular Transport Inc.
AMTI.O :
* APPLIED MOLECULAR TRANSPORT ANNOUNCES POSITIVE TOP-LINE
PHASE 2
RESULTS FROM FILLMORE TRIAL OF ORAL AMT-101 IN PATIENTS WITH
CHRONIC POUCHITIS
* APPLIED MOLECULAR TRANSPORT INC. - AMT-101 DEMONSTRATED
FAVORABLE CLINICAL ACTIVITY AND APPEARED SAFE AND WELL-TOLERATED
* APPLIED MOLECULAR TRANSPORT INC. - TREATMENT EMERGENT
ADVERSE
EVENTS WERE MOSTLY MILD TO MODERATE, WITH ONLY ONE SERIOUS
ADVERSE EVENT (SAE) OBSERVED
Source text for Eikon: ID:nGNXk5jpD
Further company coverage: AMTI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Applied Molecular Transport.
See all newsApplied Molecular Transport Inc. expected to post a loss of 50 cents a share - Earnings Preview
Brief: Applied Molecular Transport Inc. - On Oct 23 Got Written Notice Nasdaq Had Granted Co's Request For Continued Listing On Nasdaq
U.S. STOCKS ON THE MOVE-Boston Scientific, Rockwell Medical, Visa
U.S. STOCKS ON THE MOVE-Fox Corp, Cisco Systems, Darden Restaurants
Applied Molecular rises on merger deal with Cyclo Therapeutics